Targeted population screening of late onset Pompe disease in unspecified myopathy patients for Korean population

Jung Hwan Lee, Jin Hong Shin, Hyung Jun Park, Sook Za Kim, Young Mi Jeon, Hye Kyoung Kim, Dae Seong Kim, Young Chul Choi

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

We performed targeted population screening of late onset Pompe disease (LOPD) in unspecified myopathy patients, because early diagnosis is difficult due to its heterogeneous clinical features. We prospectively enrolled 90 unrelated myopathic patients who had one or more signs out of five LOPD-like clinical findings (proximal weakness, axial weakness, lingual weakness, respiratory difficulty, idiopathic hyperCKemia). Acid alpha glucosidase activity was evaluated with dried blood spot and mixed leukocyte simultaneously. For a final diagnosis of LOPD, 16 patients with decreased enzyme activity were genotyped by GAA molecular analysis. We found two patients with LOPD (2.2%), and the remaining 14 patients had at least one G576S or E689K mutation, known as the pseudodeficiency allele. Acid alpha glucosidase activity of LOPD patients was significantly lower than that of patients with at least one pseudodeficiency allele (p = 0.017). This study is the first LOPD screening study for targeted Korean population, and more generally, an Asian population. Our findings suggest that for diagnosis of LOPD in Asian population, modified cutoff value of acid alpha glucosidase activity with dry blood spot considering that of patients having heterozygote pathogenic variants or pseudodeficiency alleles may reduce time and cost requirements and increase the comfort of patients.

Original languageEnglish
Pages (from-to)550-556
Number of pages7
JournalNeuromuscular Disorders
Volume27
Issue number6
DOIs
Publication statusPublished - 2017 Jun

Fingerprint

Glycogen Storage Disease Type II
Muscular Diseases
Population
alpha-Glucosidases
Alleles
Acids
Late Onset Disorders
Heterozygote
Tongue
Early Diagnosis
Leukocytes
Costs and Cost Analysis
Mutation

All Science Journal Classification (ASJC) codes

  • Pediatrics, Perinatology, and Child Health
  • Neurology
  • Clinical Neurology
  • Genetics(clinical)

Cite this

Lee, Jung Hwan ; Shin, Jin Hong ; Park, Hyung Jun ; Kim, Sook Za ; Jeon, Young Mi ; Kim, Hye Kyoung ; Kim, Dae Seong ; Choi, Young Chul. / Targeted population screening of late onset Pompe disease in unspecified myopathy patients for Korean population. In: Neuromuscular Disorders. 2017 ; Vol. 27, No. 6. pp. 550-556.
@article{3b84a2a878864bbeacc35e11430b2cc5,
title = "Targeted population screening of late onset Pompe disease in unspecified myopathy patients for Korean population",
abstract = "We performed targeted population screening of late onset Pompe disease (LOPD) in unspecified myopathy patients, because early diagnosis is difficult due to its heterogeneous clinical features. We prospectively enrolled 90 unrelated myopathic patients who had one or more signs out of five LOPD-like clinical findings (proximal weakness, axial weakness, lingual weakness, respiratory difficulty, idiopathic hyperCKemia). Acid alpha glucosidase activity was evaluated with dried blood spot and mixed leukocyte simultaneously. For a final diagnosis of LOPD, 16 patients with decreased enzyme activity were genotyped by GAA molecular analysis. We found two patients with LOPD (2.2{\%}), and the remaining 14 patients had at least one G576S or E689K mutation, known as the pseudodeficiency allele. Acid alpha glucosidase activity of LOPD patients was significantly lower than that of patients with at least one pseudodeficiency allele (p = 0.017). This study is the first LOPD screening study for targeted Korean population, and more generally, an Asian population. Our findings suggest that for diagnosis of LOPD in Asian population, modified cutoff value of acid alpha glucosidase activity with dry blood spot considering that of patients having heterozygote pathogenic variants or pseudodeficiency alleles may reduce time and cost requirements and increase the comfort of patients.",
author = "Lee, {Jung Hwan} and Shin, {Jin Hong} and Park, {Hyung Jun} and Kim, {Sook Za} and Jeon, {Young Mi} and Kim, {Hye Kyoung} and Kim, {Dae Seong} and Choi, {Young Chul}",
year = "2017",
month = "6",
doi = "10.1016/j.nmd.2017.03.005",
language = "English",
volume = "27",
pages = "550--556",
journal = "Neuromuscular Disorders",
issn = "0960-8966",
publisher = "Elsevier Limited",
number = "6",

}

Targeted population screening of late onset Pompe disease in unspecified myopathy patients for Korean population. / Lee, Jung Hwan; Shin, Jin Hong; Park, Hyung Jun; Kim, Sook Za; Jeon, Young Mi; Kim, Hye Kyoung; Kim, Dae Seong; Choi, Young Chul.

In: Neuromuscular Disorders, Vol. 27, No. 6, 06.2017, p. 550-556.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Targeted population screening of late onset Pompe disease in unspecified myopathy patients for Korean population

AU - Lee, Jung Hwan

AU - Shin, Jin Hong

AU - Park, Hyung Jun

AU - Kim, Sook Za

AU - Jeon, Young Mi

AU - Kim, Hye Kyoung

AU - Kim, Dae Seong

AU - Choi, Young Chul

PY - 2017/6

Y1 - 2017/6

N2 - We performed targeted population screening of late onset Pompe disease (LOPD) in unspecified myopathy patients, because early diagnosis is difficult due to its heterogeneous clinical features. We prospectively enrolled 90 unrelated myopathic patients who had one or more signs out of five LOPD-like clinical findings (proximal weakness, axial weakness, lingual weakness, respiratory difficulty, idiopathic hyperCKemia). Acid alpha glucosidase activity was evaluated with dried blood spot and mixed leukocyte simultaneously. For a final diagnosis of LOPD, 16 patients with decreased enzyme activity were genotyped by GAA molecular analysis. We found two patients with LOPD (2.2%), and the remaining 14 patients had at least one G576S or E689K mutation, known as the pseudodeficiency allele. Acid alpha glucosidase activity of LOPD patients was significantly lower than that of patients with at least one pseudodeficiency allele (p = 0.017). This study is the first LOPD screening study for targeted Korean population, and more generally, an Asian population. Our findings suggest that for diagnosis of LOPD in Asian population, modified cutoff value of acid alpha glucosidase activity with dry blood spot considering that of patients having heterozygote pathogenic variants or pseudodeficiency alleles may reduce time and cost requirements and increase the comfort of patients.

AB - We performed targeted population screening of late onset Pompe disease (LOPD) in unspecified myopathy patients, because early diagnosis is difficult due to its heterogeneous clinical features. We prospectively enrolled 90 unrelated myopathic patients who had one or more signs out of five LOPD-like clinical findings (proximal weakness, axial weakness, lingual weakness, respiratory difficulty, idiopathic hyperCKemia). Acid alpha glucosidase activity was evaluated with dried blood spot and mixed leukocyte simultaneously. For a final diagnosis of LOPD, 16 patients with decreased enzyme activity were genotyped by GAA molecular analysis. We found two patients with LOPD (2.2%), and the remaining 14 patients had at least one G576S or E689K mutation, known as the pseudodeficiency allele. Acid alpha glucosidase activity of LOPD patients was significantly lower than that of patients with at least one pseudodeficiency allele (p = 0.017). This study is the first LOPD screening study for targeted Korean population, and more generally, an Asian population. Our findings suggest that for diagnosis of LOPD in Asian population, modified cutoff value of acid alpha glucosidase activity with dry blood spot considering that of patients having heterozygote pathogenic variants or pseudodeficiency alleles may reduce time and cost requirements and increase the comfort of patients.

UR - http://www.scopus.com/inward/record.url?scp=85017512265&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85017512265&partnerID=8YFLogxK

U2 - 10.1016/j.nmd.2017.03.005

DO - 10.1016/j.nmd.2017.03.005

M3 - Article

C2 - 28433475

AN - SCOPUS:85017512265

VL - 27

SP - 550

EP - 556

JO - Neuromuscular Disorders

JF - Neuromuscular Disorders

SN - 0960-8966

IS - 6

ER -